OptimizeRx Corporation (OPRX) SEC Filings & Earnings Calls

Customer concentration

“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.” · word for word

Major customer loss

“the Company did not generate revenue during the current period from a customer that accounted for approximately 10% of total revenue in fiscal 2025.” · word for word

Macroeconomic uncertainty

“These macroeconomic factors have contributed to more measured customer spending patterns, which was a factor in our 21% revenue decline for the six months ended June 30, 2026.” · word for word

Seasonality

“the first quarter tends to reflect lower activity levels and lower revenue, with gradual increases in the following quarters.” · word for word

Concentrated customer revenue decline; net revenue retention drop indicates churn risk.

“Net revenue retention 90% vs 121% YoY; revenue decline concentrated among a small number of customers.”

Leadership transition may cause short-term disruption.

“Departure of CFO and appointment of new CFO and CAO.”

Increased share reserve may lead to shareholder dilution over time.

“Equity plan share increase approved.”

Potential disruption in commercial leadership; non-compete and non-solicit provisions in place.

“Separation agreement includes 12-month non-compete and non-solicit clauses.”

Customer concentration

“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.” · word for word

Material weakness in internal controls

“a material weakness in our internal control over financial reporting was identified which related to controls ensuring that data received from third-party service organizations were complete and accurate” · word for word

Key customer loss

“the Company did not generate revenue during the current period from a customer that accounted for approximately 10% of total revenue in fiscal 2025. While the master service agreement with this customer remains in effect, future revenue is uncertain and may be lower than in prior periods.” · word for word

New debt imposes financial covenants (fixed charge coverage ≥1.20x, total net leverage ≤2.75x) and security interests.

“Covenants include minimum fixed charge coverage ratio of 1.20:1.00 and maximum total net leverage ratio of 2.75:1.00.”

Material weakness in internal control over financial reporting

“the Company identified a material weakness in internal control over financial reporting related to controls ensuring data received from third-party service organizations were complete and accurate.” · word for word

Low say-on-pay support

“At our 2025 Annual Meeting, 58.53% of votes cast were in favor of our 2024 executive compensation program.” · word for word

Related-party transaction concentration

“OptimizeRx has entered into a Reseller Agreement with EVERSANA whereby EVERSANA may offer OptimizeRx solutions to its life sciences customers from which we generate revenue.” · word for word

Customer concentration

“Our top five customers represented approximately 47% of revenue for the year ended December 31, 2025.” · word for word

Material weakness in internal controls

“The Company has identified a material weakness in the Company's internal control over financial reporting.” · word for word

Regulatory risk from MFN pricing

“If our customers' drug prices are reduced as a result of MFN pricing initiatives or other similar regulations, our business could be adversely affected by our customers reducing their marketing and advertising spend.” · word for word

High leverage and debt service

“Servicing debt and funding other obligations requires a significant amount of cash, and our ability to generate sufficient cash depends on many factors, some of which are beyond our control.” · word for word

Channel partner concentration

“We generated 62% and 57% of our revenue through our two largest channel partners in 2025 and 2024, respectively.” · word for word

MFN pricing uncertainty may cause customers to reduce discretionary spending and shorten contract durations.

“We are beginning to see increased market volatility, driven in part by uncertainty surrounding Most Favored Nation (MFN) pricing. In response, we believe some customers are taking a more measured approach to discretionary spending and contract duration.”

Revenue concentration in top 20 pharma declined from 65% to 52%, indicating potential customer churn or diversification.

“Percent of total revenue attributable to top 20 pharmaceutical manufacturers │ 52 │ % │ 65 │ %” · word for word

Customer concentration

“Our top five customers represented approximately 49% and 44% of our revenue for the years ended December 31, 2024 and 2023, respectively.” · word for word

Macroeconomic uncertainty

“Unfavorable conditions in the economy may negatively affect the growth of our business and our results of operations.” · word for word

Customer concentration: top 20 pharma manufacturers account for 56% of revenue, down from 65%.

“Percent of total revenue attributable to top 20 pharmaceutical manufacturers 56% vs 65%.”

Net revenue retention declined from 127% to 120%, indicating potential slowdown in upselling/cross-selling.

“Net revenue retention 120% vs 127%.”